Holen Sie sich die Stockscreener-App
254.49
0.04%
0.10
Handel nachbörslich:
255.14
0.65
+0.26%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie stock trades steady as investors focus on Skyrizi and Rinvoq growth after mixed quarter - ad-hoc-news.de
AbbVie (ABBV) Wins EU Approval For Boey Frown Line Treatment In Europe - Yahoo Finance UK
AbbVie granted EU nod for Boey anti-wrinkle therapy (ABBV:NYSE) - Seeking Alpha
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes - GlobeNewswire Inc.
AbbVie stock holds gains as investors weigh Skyrizi and Rinvoq growth - ad-hoc-news.de
Is AbbVie Inc (ABBV) Overvalued After 4.2% Rally? GF Value Says - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV) - The Globe and Mail
AbbVie stock trades steadily as investors weigh Humira erosion and pipeline progress - ad-hoc-news.de
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter? - TradingView
Is AbbVie (NYSE:ABBV) Fully Valued After Tepkinly? - Kalkine Media
Why AbbVie (ABBV) Stock Is Up Today - Quiver Quantitative
AbbVie Inc Stock (ABBV) Moved Up by 3.32% on Jul 16: What Signal Does It Send? - TradingKey
Is AbbVie (ABBV) Fully Priced Despite Tepkinly Approval And Cash Flow? - simplywall.st
AHA urges court to reject AbbVie bid to change 340B program rules - EIN News
AbbVie stock holds steady as its diversified portfolio underpins long-term growth - ad-hoc-news.de
ABBV Maintained by Citigroup -- Price Target Raised to $260 - GuruFocus
Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise? - TradingView
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap - 24/7 Wall St.
Nxera Pharma Webinar for Financial Results Presentation - GlobeNewswire Inc.
Red day on Tuesday for AbbVie stock after losing 1.31% - StockInvest.us
AbbVie (ABBV) Stock Looks Fully Priced After A 152% Run - Yahoo Finance
AbbVie Tokenized Stock price today, ABBVX to USD chart, marketcap and volume - CryptoSlate
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie (ABBV) Faces Seventh Consecutive Loss Amid Mixed Sentimen - GuruFocus
AbbVie extends slide to a seventh straight session - MSN
AbbVie price seeks a supportive bottomForecast today14-07-2026 - Economies.com
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic? - Yahoo! Finance Canada
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development - Investing News Network
AbbVie stock: Is ABBV outperforming the healthcare sector? - MSN
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb - The Globe and Mail
AbbVie pharmaceutical project moves forward in Durham: 'Huge deal' - ABC11 News
Apogee Therapeutics (NASDAQ: APGE) backs AbbVie’s $135.11‑per‑share all‑cash deal - Stock Titan
ABBV Maintained by UBS -- Price Target Raised to $260 - GuruFocus
BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating - marketscreener.com
ABBV Maintained by BMO Capital -- Price Target Raised to $300 - GuruFocus
UBS Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating - marketscreener.com
Why is AbbVie stock climbing today? By Investing.com - Investing.com Canada
BMO raises Abbvie stock price target to $300 on Skyrizi strength - Investing.com
AbbVie stock holds steady on its antibody and immunology franchise - ad-hoc-news.de
AbbVie Employees Across Asia Unite Through Week of Possibilities by Serving and Supporting Communities - PR Newswire
AbbVie stock holds steady after a new U.S. market backdrop - ad-hoc-news.de
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Eli Lilly & Co (LLY) - The Globe and Mail
BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $276 - Moomoo
AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Sco - GuruFocus
West Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its Business - Yahoo Finance
ABBV Maintained by B of A Securities -- Price Target Raised to $276 - GuruFocus
Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner - AOL.com
AbbVie Inc. Stock 12‑Month Price Target Raised to $263.72, Implies 6% Upside - TradingView
Wall Street Lifts Obesity Drug Targets for Eli Lilly and AbbVie as Medicare Coverage Expands - Investorideas.com
ABBV Maintains Overweight Rating -- Price Target Raised to $295 - GuruFocus
BofA Securities Adjusts AbbVie Price Target to $276 From $234 - marketscreener.com
ABBV Maintained by RBC Capital -- Price Target Raises to $260 - GuruFocus
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $276 to $295 - Moomoo
AbbVie's Q2 Results Expected to be Inline With Expectations, RBC Says - marketscreener.com
Dividend Roundup: Costco, Phillips 66, Abbott Labs, AbbVie, and more (DVY:NASDAQ) - Seeking Alpha
RBC Raises Price Target on AbbVie to $280 From $260, Keeps Outperform Rating - marketscreener.com
Wells Fargo Adjusts Price Target on AbbVie to $295 From $260 - marketscreener.com
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
AbbVie (NYSE:ABBV): Dividend Stability Under The Spotlight - Kalkine Media
JPMorgan Adjusts Price Target on AbbVie to $280 From $260 - marketscreener.com
ABBV Maintains Buy Rating -- Price Target Raised to $261 - GuruFocus
ABBV Maintained by JP Morgan -- Price Target Raised to $280 - GuruFocus
ABBV Leads Its Peer Group. You Pay For That - Trefis
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth - TradingView
0.10%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):